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Imaging through the visual system in Alzheimer’s disease, with the technology currently in widespread use for the diagnosis and
managementof eye disease such as glaucomaand macular degeneration, is proving to be promising.In vivo cross-sectionimaging
during an annual comprehensive eye exam has been available for a decade for glaucoma and macular degeneration, and this
same imaging, using Optical Coherence Tomography, has been demonstrated to show deﬁcits speciﬁc to AD and mild cognitive
impairment. These deﬁcits are in the form of nerve ﬁber layer tissue drop out in the retina and optic nerve. The retrograde loss of
nerve ﬁber layer tissue in the retina and optic nerve may be an early biomarker of AD, and these deﬁcits in the nerve ﬁber layer of
the retina and optic nerve may be the earliest sign of AD, even prior to damage to the hippocampal region that impacts memory.
1.Introduction
Biomarkers for the early diagnosis, management, and treat-
ment of Alzheimer’s disease (AD) are important. In vivo
cross-section imaging during an annual comprehensive eye
exam with a dilated pupil has been available for a decade
for glaucoma and macular degeneration, and this same
imaging, using Optical Coherence Tomography (OCT), has
been demonstrated to show deﬁcits speciﬁc to AD [1–7]a n d
mild cognitive impairment (MCI) [2]. These deﬁcits are in
the form of nerve ﬁber layer tissue drop out in the retina and
optic nerve. The retrograde loss of nerve ﬁber layer tissue
in the retina and optic nerve may be an early biomarker of
AD, and these deﬁcits in the nerve ﬁber layer of the retina
and optic nerve may be the earliest sign of AD, even prior
to damage to the hippocampal region that impacts memory.
The OCT technology used to identify nerve ﬁber layer
defects in AD reported in the literature is an older version
often referred to as Time Domain-OCT. Time Domain-
OCT (Time-OCT) only resolved the retina to approximately
ten microns, whereas newer clinical OCT imaging systems
High Deﬁnition/Resolution/Fourier/Spectral Domain-OCT
(HDR-OCT) can resolve the retina to ﬁve microns or less,
acquireimages faster, reregister retinal location,anddoes not
requirethedilationofthepupilsoftheeye.Fasteracquisition
is important for patients with cognitive impairment such
as AD. The ability to reregister exact location enables more
accurate followup and longitudinal study.
OCT is similar to ultrasound, but instead of measuring
echoed sound waves, it measures the echoed time delays of
a reﬂected light beam. As the beam is scanned, there is a
cross-sectional image generated. The OCT used for ocular
imaging has a ﬁber optic delivery system coupled with a slit-
biomicroscope. The patient sits with their head positioned
in a chin rest and the experience is similar to having a
photograph taken of the eye. This type of imaging can easily
be incorporated into annual eye exams for those with AD.
2.History
The ﬁrst published reports of imaging in vivo retinal tissue
with OCT were in 1993 [8, 9], and the ﬁrst reports of OCT
use showing signiﬁcant deﬁcits in the eyes of participants
with AD were in 2001 [5]. The technology has evolved
considerably since these early works were published. OCT
technology and its application in the eye had origins in
the Department of Electrical Engineering and Computer
Science at Massachusetts Institute of Technology where
James G. Fujimoto, Ph.D., a professor in computer sciences2 International Journal of Alzheimer’s Disease
and electrical engineering along with his students had
collaborated with Carmen A. Puliaﬁto, MD who at the time
was aﬃliated with the Massachusetts Eye and Ear Inﬁrmary
(MEEI) [10]. Another student working with Dr. Fujimoto
contributed with the idea to generalize axial scanned images
totransverse images[10]andpublishedtheprecursorimages
of ex vivo retina [11] and these are considered to be the
ﬁrst illustration of OCT use. Joel S. Schuman, MD was a
glaucoma fellow at MEEI in 1989 and was doing work in the
laboratoryofDr.Puliaﬁto.Heeventuallyworkedcloselywith
the New England Eye Center at Tufts Medical School where
over 10,000 patients were imaged with the initial prototype
[10]. Clinical studies took place between 1994 and 1995
and Carl Zeiss Meditec made available the ﬁrst commercial
instrument in 1996, the Stratus-OCT [10]. Optovue, Carl
Zeiss Meditec, Heidelberg Engineering, Topcon Medical
Systems, and Bioptigenare some of the other companies that
have developed imaging technology using the HDR-OCT
systems.
All publications to date, using OCT technology in
the study of AD, have used the Stratus-OCT from Carl
Zeiss Meditec which was the Time-OCT. The parameters
are longitudinal axial resolution <10 microns in tissue,
transverse resolution 20 microns in tissue, scan speed
400A scans per second, longitudinal depth 2mm in tissue,
and an optical source of superluminescent diode at 840
nanometers [12]. The newer HDR-OCT from Carl Zeiss
Meditec; the Cirrus/HD-OCT has improvements that will
make the technology more eﬀective in AD. Among the
improvements is the ability to reregister the images assuring
more precise, repeat measurements for longitudinal studies.
The parameters are longitudinal axial resolution <5m i c r o n s
in tissue, transverse resolution 15 microns in tissue, scan
speed 27,000 scans per second, longitudinal depth 2mm in
tissue, and an optical source of superluminescent diode at
840 nanometers [13]. Figure 1 shows Stratus-OCT images of
the nerve ﬁber layer in a normal age control participant that
was age matched to the AD participant, a participant with
AD and a participant with both glaucoma and Parkinson’s
disease (not age matched).
While it is likely that HDR-OCT technology will become
an integral part of the diagnosis and management of
AD, diﬀerentiating the optic nerve ﬁber losses and retinal
changes from common age-related ocular disease, and in
particular glaucoma will remain clinically demanding. The
two diseases, AD and glaucoma, impact the same visual
pathways early in their disease processes. Additionally both
diseases can result in subtle changes in the functional aspects
of vision.
The OCT imaging picks up the deﬁcits related to
AD as structural drop out due to retrograde degeneration
from the brain tissue in visual processing areas such as
the visual association area, Brodmann 19. Further, the
degeneration in the visual association area may be one
of the earliest brain tissues damaged by AD, even before
the memory/hippocampal areas. That neurodegenerative
pathology of AD originates in the visual association area
is indicated in the studies by McKee and colleagues of
autopsied brains in the Framingham Heart Study [14].
McKee and colleagues found that in the visual association-
Brodmann 19 area of over 50% of those that had been
classiﬁed as being cognitively normal, having no memory
impairments, there were ﬁndings related to AD such as
beta amyloid and neuroﬁbrillary tangles. Similar structural
ﬁndings werecommonlyassociated withAlzheimer’sdisease.
In some of the cognitively normal cases, there was no AD-
related pathology in the hippocampus area which processes
memory, but there was AD related pathology in the Visual
Association-Brodman 19 [14].
Losses in visual function attributed to AD have many
aspects in common with the functional losses in glaucoma.
Both diseases show structural changes early in their course in
the visual cortex [15, 16] and lateral geniculate nucleus [17–
19]. The ability to detect motion is reduced in AD [20, 21];
there are visual ﬁeld defects [22, 23]; contrast sensitivity
deﬁcits in the lower spatial frequencies have been reported
in participants with AD [24]. Glaucoma also impacts lower
spatial frequencies in contrast sensitivity and producesvisual
ﬁeld defects [25].
3.Glaucomaand AD[26]
There is a more aggressive destruction of structure and
function when patients have both AD and glaucoma [27].
Glaucoma is a painless and insidious disease process and
oftengoesundetected.Glaucomaimpactsuptothreemillion
Americans, but only one half of those with glaucoma are
aware they have it. Glaucoma is responsible for 9–12% of
blindness in the United States. Glaucoma is the leading
cause of blindness among African Americans and Hispanics.
Those over the age of 60 of any race are at greater risk of
developing glaucoma and it is estimated that 8% of those
overtheageof80haveelevatedIOP.GlaucomaandADaﬀect
the magnocellular visual processing. The magnocellular-
mediated visual functions are those that are not easily
assessed during conventional eye examinations such as
motion processing and contrast sensitivity function. There
are losses in the magnocellular layers of the lateral geniculate
nucleus in glaucoma [17, 18]. The lateral geniculate nucleus
neurons early on in the glaucoma disease process show
signiﬁcant shrinkage and are observed even before nerve
ﬁber loss in the optic nerve with conventional direct viewing
methods [28, 29]. HDR-OCT likely identiﬁes these early
losses. A single case study reported in the literature by Gupta
and colleagues [15] regarding changes in the visual cortex
in human glaucoma indicated reductions in autopsied tissue
in the area below the calcarine sulcus compared to normal
control. This region of change corresponded to an area of
superior visual ﬁeld loss that had been identiﬁed in the
participant prior to death. Structural defects speciﬁc to the
magnocellular visual pathway have also been identiﬁed in
individuals with AD even in brain areas devoid of plaques
and neuroﬁbrillary tangles. The magnocellular visual path-
way shows signs of individual cell drop out in the primary
visual cortex of AD individuals [16]. Neuroﬁbrillary tangles
and amyloid plaques have been identiﬁed in the lingual and
cuneal gyri of participants with AD, and these correlate withInternational Journal of Alzheimer’s Disease 3
theincidenceoffunctionalvisualﬁeldlossinADparticipants
[22]. The magnocellular layers in the lateral geniculate
nucleushave beenshown tohave plaquesassociated with AD
[19]. The visual association area processes signals from the
magnocellular visual pathway.
GlaucomaandADhavedisruptionsincircadianfunction
[30]. “Sundowning” may be caused by disruptions in the cir-
cadian rhythm of AD patients. Sundowning is a general term
describing symptoms such as sleep disturbance, nocturnal
delirium, disorientation at the onset of darkness, night-time
activity, and agitation [31]. Disturbances in the circadian
rhythm occur in AD patients, with rates ranging from 12%
[32] to 25% [33]. AD is associated with changes in the
suprachiasmatic nucleus [34, 35].
The eye’s intraocular pressure follows a circadian rhythm
withincreases inintraocular pressure atnight [36–39].There
are reports that found greater ﬂuctuation and range in
intraocular pressure in individuals with glaucoma compared
to healthy control individuals [39, 40]. Studies by Liu and
colleagues [38] found that the larger the diurnal variation
and ﬂuctuation of intraocular pressure, the greater the
risk for structural damage due to glaucoma. Intraocular
ﬂuctuation may not be a risk factor, but actually an early
symptom of glaucoma, as the disease impacts the optic
nerve and the axons leading to brain structures processing
circadian function. Light has a strong inﬂuence on the
circadian system and the timing and duration of exposure to
daylightcanimpactcircadianphases,melatoninsuppression,
physiological responses, and alertness [41]. A previously
unknown photoreceptor that was dissimilar to both rod cells
and cone cells was identiﬁed by Berson and colleagues [42].
These cells are retinal ganglion cells that directly innervate
the suprachiasmatic nucleus and are reactive to light even
when all synaptic input from rod cells and cone cells is
blocked. Damage anywhere along the visual pathways that
process functions related to the circadian retinal cells has
potential to disrupt circadian rhythms, and these structural
deﬁcits will result in further reduction of the nerve ﬁber
layers in the retina as measured by OCT. This would be the
case whether the site of origin is in the brain such as in AD
or in the optic nerve as in glaucoma.
Studies have identiﬁed a higher incidence of glaucoma
among those residing in nursing homes. One such study
found a higher rate of glaucoma among 112 residents with
AD compared to 774 residents without AD. The diagnosis
of glaucoma was based on visual ﬁeld defects or optic
nerve cupping observed during eye examinations. While
there may be ﬁeld defects in AD, there is generally no
optic nerve cupping. Optic nerve cupping is a biomarker
related to glaucoma. The rate of glaucoma was 25.9% for
the AD patients and 5.2% for the control nursing home
group [43]. The optic nerve may be less resistant to elevated
intraocular pressure levels with AD. A record review in a
large glaucoma clinic identiﬁed seven patients with elevated
intraocular pressures or ocular hypertension that initially
had normal visual ﬁelds and normal optic discs and had
also been diagnosed within one year of also having AD.
Among these patients, there was a more glaucomatous optic
neuropathy which was much more rapid compared to other
glaucoma patients [27]. This has also been reported to be
the case for Parkinson’s disease also [44]. Figure 1 shows
the nerve ﬁber layer deﬁcits identiﬁed with Time-OCT
in a participant that had both glaucoma and Parkinson’s
disease. Figure 1 also shows the same participants optic
nerve, demonstrating both nerve ﬁber loss and optic nerve
cupping.
A study found a higher rate of glaucoma among AD
patients compared to non-AD patients. In their study of 172
patients with AD in Japan compared to 176 age matched
controls, Tamura and colleagues [45] found those with AD
had a rate of glaucoma of 23.8% compared to only 9.9%
of the age-matched controls having glaucoma. If there are
two neurodegenerative processes such as glaucoma and AD
aﬀecting one of the major relay centers for visual function,
it is easy to appreciate that the loss in function can be
substantial.
As AD progresses causing substantial reductions in brain
volumes,theremaybeadditionalimpactonthevisualsystem
creating abnormal pressure gradients at the back of the eye
along the nerve. This can cause stress and damage to the
lamina cribrosa, the supportive tissue to the optic nerve.
When there is a lower pressure on the posterior nerve such
as was found in a study of cerebrospinal ﬂuid pressure by
Berdahl and Allingham, there is a signiﬁcantly higher rate
of glaucoma [46]. In their study, the average cerebrospinal
ﬂuid pressure was 33% lower in those with glaucoma
compared to those without a diagnosis of glaucoma. Morgan
and colleagues theorize that when the cerebrospinal ﬂuid
pressure is low, there is an inﬂuence on subarachnoid space.
Becauseofthespacelocationposteriortotheglobeandnerve
and its pressure relationships to intracranial, retrolaminar
and translaminar tissue it is as if there is damage much
like would occur with an elevation of pressure inside the
eye [47]. There is increasing evidence that low cerebrospinal
ﬂuid pressure causes glaucoma like damage [48–50]. Wostyn
and colleagues have had long standing theories regarding
changes in cranial pressure and the relationship of the
stress of change to neurodegenerative diseases including
AD and glaucoma [51], and the recent ﬁndings related to
reduced cerebrospinal ﬂuid and glaucoma are supportive
of this. Wostyn reports in a study that a subgroup of AD
participants had low cerebrospinal ﬂuid pressures and he
attributed this to brain atrophy. He further theorizes, as
did Morgan and colleagues, that this produces an abnormal
high translamina pressure diﬀerence and this is what leads
to the higher incidence of glaucoma among those with AD
[52].
The relationship between AD and glaucoma remains
poorly understood. Published studies look at more advanced
dementia in already diagnosed AD and residents in nursing
homes with AD. To date there are no published studies
investigating glaucoma in Mild Cognitive Impairment or in
mild AD. This still leaves the possibility that the two diseases
are unrelated, but because they aﬀect the same axonal
structures and visual pathways the result is an expression
of the vision losses related to glaucoma at an earlier stage
of the disease. It is estimated that thirty to ﬁfty percent of
ganglion cells and ﬁbers in the visual pathway are damaged4 International Journal of Alzheimer’s Disease
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Figure 1: The top three images depict the nerve ﬁber layer (NFL) generated by the older technology; Stratus-OCT. The y axis is NFL
thickness in microns and the x axis is the circumference of the optic nerve in degrees; TEMP = temporal, SUP = superior, NAS = nasal and
INF = inferior.None ofthe participants had a signiﬁcantrefractive error. The top left ﬁgure is from a 73 year old control participant with no
knownrisk factors for glaucoma; Caucasianand age matched to the AD participant. The NFL had an average thickness of 101 microns. The
top right image was obtained from a 72 year old participant with no known risk factors for glaucoma; Caucasian,with AD. The NFL had an
averagethicknessof75microns.ThemiddleimagewasfromaCaucasianparticipant,withnoknownriskfactorsforglaucoma;thathadboth
Parkinson’s disease and glaucoma. The average NFL thickness was 58 microns. The yellow arrows show regions of thinning hypothesized to
be due to retrograde neurologic degeneration. The red arrow indicates areas of thinning attributed to glaucoma. The bottom three images
are cross sections of the optic nerve. Sections of red indicate the nerve ﬁber layer. The bottom left image is of the control participant, the
bottom middle image is of the AD participant and the bottom right image is of the participant with both Parkinson’s disease and glaucoma.International Journal of Alzheimer’s Disease 5
by glaucoma before the disease is detected by conventional
visual ﬁeld testing of the peripheral vision [53, 54]. As AD
destroys visual pathway ﬁbers, the result may simply be
an earlier expression of the functional losses in glaucoma
because there are fewer neural reserves.
4.OcularAD-RelatedHistopathology[26,30]
AD damages the lateral geniculate nucleus [19]a n dg l a u -
coma damages the lateral geniculate nucleus early in the
respective disease processes [18]. Damage secondary to AD
also occurs in the visual association cortex and other higher
cortical areas, the primary visual cortex [16, 55], and visual
association areas [14]. Additional studies have demonstrated
deﬁcits in the retinocalcarine pathway [56–60].
Loss of retinal ganglion cells has been identiﬁed by
several groups. Such losses will be better characterized by
imaging with HDR-OCT. A study by Blanks and colleagues
[61] studied 16 individuals with ADwith an age range of76–
93.There were 19 normal individuals with an age range from
55–91. They found that within the ganglion cell layer, the
cellshaving the largest diametermay havebeen preferentially
aﬀected in AD. The cells in the magnocellular layer are larger
diameter cells.
Sadun and Bassi [60] analyzed 3 eyes from AD indi-
viduals ranging in age from 76–89 years. There was degen-
eration of the retinal ganglion cells. They found axonal
degeneration upon examining the retrobulbar optic nerves.
The degeneration was reported to be more pronounced
the more posterior the nerve. This indicated the retinal
ganglion cell loss may be secondary to retrograde axonal
degeneration. Hinton and colleagues [57] analyzed the optic
nerves of 10 individuals with AD and 10 age-matched
normal individuals ages 76–89 years. This study found
eight of the ten nerves obtained from participants with
AD compared to the controls were signiﬁcantly diﬀerent
in ﬁber count compared to the normal individuals. The
level of AD severity or duration of illness was not doc-
umented. The described ﬁndings are in contrast to the
ﬁndings of Curcio and colleagues [56]w h oe x a m i n e df o u r
AD eyes with an age range of 67–86 years as well as
the eyes from four age-matched normal individuals. The
individuals with AD had the disease for at least four years
and had severe dementia. Curcio and colleagues did not
ﬁnd diﬀerence between the eyes from participants with
AD compared to the age-matched control eyes. Davies and
colleagues [62] studied 9 AD and 7 normal eyes and found
no histopathologic evidence of diﬀerences in the retinal
ganglion cellsbetween individualswith ADand age-matched
normal individuals. With imaging using UHR-OCT, we
can now measure in vivo, without discomfort, but still
obtain detailed imaging of structures that parallel common
histologic methods, but eliminates artifacts related to tissue
movement, cell displacement, cell shrinkage or nerve ﬁber
dissipation. The UHR-OCT allows for repeat measurements
of the same participant over time with image reregistration.
The older OCT technology had limits in reregistering
location.
5.RetinalPhotographsand AD[26,30]
Using photographs, Hedges and colleagues [59] studied the
retinal nerve layer of 26 participants in various stages of
AD and 23 age-matched controls with ages of both groups
ranging from 52 to 93. They found a greater amount of
nerve ﬁber loss in the individuals with AD compared to
age-matched normal individuals. There was a trend towards
increasing nerve ﬁber layer abnormalities with progression
and duration of the disease. However, it was not statistically
signiﬁcant.
In the retinal photographs of 22 AD participants and
24 normal age-matched participants, Tsai and colleagues
[63] found that ﬁve of the AD participants had nerve
ﬁber loss compared to one of the control participants. The
photographic method showed that there was a signiﬁcant
correlation in degree of segment optic nerve pallor and
the duration of AD. Trends were identiﬁed in the segment
pallor and the mean Alzheimer’s disease Assessment Scale
(cognitive, no cognitive and total). Duration and severity
of AD probably impact optic nerve ﬁndings. Conventional
photographic studies that include only early-onset AD may
result in conclusions that the optic nerve is not impacted
(and therefore no change in the ganglion cells) because the
sample studied has not had the progression of the disease
to the point where the ganglion cells have been impacted.
However, in the study using OCT looking at both AD and
MCI, Pacquet and colleagues found no statistical diﬀerence
between AD and MCI indicating that the OCT imaging may
bemoresensitivetoearlydiseasethananyprevioushistologic
or photographic method.
6.Optic NerveFiber Imaging and ADwith
Stratus-OCT[26]
Parisi and colleagues [5] used the older version of Time-
OCT to assess the optic nerve ﬁber layer thickness in 17
AD participants and 14 age-matched control participants
and found a signiﬁcant reduction in nerve ﬁber thickness
in the AD individuals compared to the age-matched control
participants. The age range was from 63 to 77. The study
included participants with mild severity of cognitive impair-
ment. OCT has the ability to measure the thickness of the
macula.
EarlyreportsusingimagingtechnologiesotherthanOCT
failed to show deﬁcits in the nerve ﬁber layer associated
with AD. Scanning laser polarimetry (GDx Nerve Fiber
Analyzer) assesses the nerve ﬁber layer by measuring changes
in the polarization due to the bi-refringent properties of the
n e r v eﬁ b e rl a y e r .O n c ea l i g n e d ,t h ei m a g ei sa c q u i r e di n0 . 7
seconds. Kergoat and colleagues [64] used this technique
and found no diﬀerences in the optic nerve ﬁber layer in
30individualswith early-stage AD,comparedtoage-matched
normal individuals. The same group failed to ﬁnd nerve
ﬁber layer deﬁcits using yet another imaging technology
[65]. The technology, scanning laser tomography (Hei-
delberg Retinal Tomograph-HRT), uses confocal scanning6 International Journal of Alzheimer’s Disease
lasers to provide real-time three-dimensional images and
measurements of the optic disc and surrounding area.
Parameters that can be measured include cup area, disc
area, cup volume, rim volume, cup/disc area ratio, and rim
dim/disc area. Once aligned, images are obtained in 1.5
seconds.
Iseri and colleagues used OCT imaging technology to
measure macular volume[4]an df oun dth atof28ey est es t ed
in group of Alzheimer’s participants there was signiﬁcant
thinning of the macula compared to 30 eyes tested from
a group of control participants. Iseri and colleagues also
measured thinning of the retinal nerve ﬁber layer in those
with AD compared to age-matched control participants and
thatboththemacularthinning andnerveﬁber layerthinning
were correlated with the severity of cognitive function.
Berisha and colleagues [66] have reported the only study
to have looked at all three groups; glaucoma, AD, and
age-matched control participants. The group of glaucoma
participantshadan averageageof71,ADparticipantshad an
average age of 76, and the age matched control participants
h a da na v e r a g ea g eo f7 2 .T h e yf o u n ds i g n i ﬁ c a n td i ﬀerences
between the groups in the superior quadrant thickness of the
nerve ﬁber layer when measured with OCT and abnormal
cup to disc ratios in only the glaucoma group. The glaucoma
participants had an average of 106mm in the superior optic
nerve ﬁber layer; the AD participants had an average of
90mm, and the control participants an average of 115mm.
This study demonstrated that the deﬁcits identiﬁed with
OCT are unique to AD and are not undiagnosed ocular
pathology such as glaucoma. Superior nerve ﬁber layer
deﬁcits were also identiﬁed in those with AD compared to
normal age-matched control participants in a study by Lu
and colleagues [6]. This study looked at 22 participants with
AD and 22 age-matched control participants. This study,
unlike other studies using OCT, found an increase in the
cup to disc ratio of participants with AD compared to age-
matched control participants as well as inferior nerve layer
deﬁcits compared to the age matched control participants.
While not an OCT study, Danesh-Meyers and colleagues
used the ocular imaging technology using scanning laser
Tomography, HRT [67], and also found an increase in cup
to disc ratios in addition to the deﬁcits in nerve ﬁber layers.
If intraocular pressure is the only criteria utilized to rule out
glaucoma in studies, this may result in the inclusion of a
variety of glaucomas: normal tension glaucomas, glaucomas
that have a wide ﬂuctuation in pressure, and glaucomas that
had at baseline/young age very low pressures that are now
within normal, but high normal ranges. An increased cup to
disc ratio, also called cupping, is the physical phenomenon
hypothesized to be caused by pressure at the posterior of the
eye upon the nerve resulting in cell death and subsequently
loss of the ﬁbers themselves. The nerve has fewer nerve ﬁbers
along the edge or rim of the optic nerve. As more and more
ﬁbers are lost, the nerve starts to be hollowed out and then
ﬂattened. Figure 1 shows OCTimages ofthe cup to disc ratio
in a normal age-matched control participant, a participant
withAD,and aparticipant withParkinson’s disease as well as
glaucoma.
Using the older OCT technology, Paquet and colleagues
[2] studied a group of participants with both MCI and
AD and looked at 15 noncognitively impaired age-matched
participants, 14 participants with mild AD, 12 participants
with moderate AD, and 23 participants with mild cognitive
impairment. They found that the nerve ﬁber layer was
thinned in those with mild cognitive impairment, mild
AD, and moderate to severe AD. They also did not ﬁnd
any signiﬁcant diﬀerence between those with mild AD and
mild cognitive impairment. Even the older OCT imaging
technology with its lower resolution has the potential to
identify biomarkers of disease prior to substantial impact on
thecognitivefunctions currentlyused toidentify Alzheimer’s
disease.
The older OCT technology has also been reported to
identify deﬁcits in the nerve ﬁber layer of those with Parkin-
son’s disease compared to age-matched controls [68–70].
7.Conclusion
The visual system provides opportunity to use noninvasive
clinicaltoolstoidentify andmonitorbiomarkersofneurode-
generative diseases such as AD. The number of those with
AD in the United States is approaching 5.1 million, and this
number is expected to reach 13.2 million by the year 2050
[71]. AD is estimated to cost Americans $100 billion a year
both in direct costs and indirect costs [72].OCTimaging has
demonstratedstructuralnerveﬁberdeﬁcitsintheeyeinearly
Alzheimer’s disease as well as Mild Cognitive Impairment.
Imaging with faster technology with signiﬁcantly higher
resolution such as the Fourier/Spectral/High Resolution-
OCT may prove to be an eﬃcient, cost-eﬀective means of
identifying and monitoring biomarkers of early AD.
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